FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry and biotechnology, specifically a monoclonal antibody that binds to C1R transfectant cells modified to express on their surface a MICA polypeptide and a pharmaceutical composition containing same. Invention also relates to a method of treating or preventing cancer in a patient in need thereof using said composition, as well as a method of treating or preventing cancer in a patient using said monoclonal antibody.
EFFECT: invention effectively treats cancer in a patient due to a new approach to targeting MICA therapeutic agents.
13 cl, 11 dwg, 6 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO HUMAN NKG2D AND THEIR APPLICATION | 2008 |
|
RU2563343C2 |
| KIR3DL2 BINDING AGENTS | 2013 |
|
RU2682449C2 |
| BI- OR MULTISPECIFIC POLYPEPTIDES BINDING IMMUNE EFFECTOR CELL SURFACE ANTIGENS AND HBV ANTIGENS FOR TREATMENT OF BV INFECTIONS AND ASSOCIATED CONDITIONS | 2014 |
|
RU2671089C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND APPLICATION THEREOF | 2017 |
|
RU2793445C2 |
| PROTEINS BINDING SPECIFIC MEMBRANE PROSTATE ANTIGEN, AND RELATED COMPOSITIONS AND METHODS | 2012 |
|
RU2632647C2 |
| HUMANISED ANTIBODIES WITH INCREASED STABILITY | 2015 |
|
RU2684703C2 |
| BLOCKADE CD73 | 2015 |
|
RU2746804C2 |
| BINDING PROTEINS AND METHODS FOR USE THEREOF | 2015 |
|
RU2701434C2 |
| MICA/B ANTIBODIES AND METHODS OF USE | 2019 |
|
RU2821021C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | 2018 |
|
RU2781116C1 |
